The effect of Christm in treatment of female sexual disorder

Phase 3

Recruiting

Conditions: F52.22
Female sexual arousal disorder
Female sexual disorder(FSD).

Registration Number: IRCT20140525017827N10

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 74

Inclusion Criteria

Healthy menstruating women with regular menstrual cycles(between 28-34 days) between 18-35 years of age
Being married
Documented clinical diagnosis of FSD based on FSFI score.
Body mass index (BMI)=LT30.
Suffering from FSD for more than 6 months.
Nomal sexual function in partner
Agree not to use any other form of herbal or hormonal therapies for treatment of sexual dysfunction
Women using non hormonal method of contraception to prevent pregnancy.

Exclusion Criteria

Pregnancy or attempting to conceive.
Breastfeeding within 3 months prior to the study.
Having marital discord.
Receiving androgen therapy within 3 months of recruitment.
Consuming any form of hormonal contraceptive.
Consuming drug with a potential to cause sexual dysfunction (such as selective serotonin reuptake inhibitors, tricyclic antidepressants, antihypertensive drugs, etc.) and receiving stations or other drugs known to impact on steroid hormone levels and women who are taking anti-coagulant or anti-platelet drugs in the previous 3 months.
Subjects with serious medical conditions such as history of breast, endometrial or other gynecological cancer at any time before study or other cancer within the last 5 years, hypertension, diabetes, tuberculosis, lupus, cardiovascular disease, thrombo-embolic disorders, neurologic or psychiatric disease were also excluded from the study.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Female sexual disorder score based on female sexual functin index( FSFI) questionnaire. Timepoint: Before and after the end of the 4-week period of treatment. Method of measurement: female sexual function index( FSFI).;Measurment of testosterone level. Timepoint: Measuring testosterone level before the study and then during the folliculate phase of their next menstural cycle on the day of 7 to 9 after the end of study. Method of measurement: Chemiluminesence Immunoassay (cl).

Secondary Outcome Measures